17 December 2015 - Amgen today announced that the European Commission has approved the use of Imlygic (talimogene laherparepvec) for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC and IVM1a), with no bone, brain, lung or other visceral disease.

For more details, go to: http://www.amgen.com/media/news-releases/2015/12/european-commission-approves-amgens-imlygic-talimogene-laherparepvec-as-first-oncolytic-immunotherapy-in-europe/